TY  - JOUR
T1  - SCreening for type 2 diabetes
AU  - Goyder E, Irwig L
Y1  - 1999/06/02
N1  - 10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
JO  - JAMA
SP  - 1986
EP  - 1988
VL  - 281
IS  - 21
N2  - 
First, the authors assume that screening merely brings forward the date
of diagnosis. Their model and their estimate of the time between onset
and clinical diagnosis are based on studies of clinically diagnosed
cases. However, a population identified by screening would include many
people whose condition would never be clinically apparent and who will
die, mainly of cardiovascular disease (CVD), before clinical diagnosis
and long before they would develop long-term microvascular
complications. The model therefore may overestimate the risks of
end-stage microvascular disease for screening-detected cases.

SN  - 0098-7484
M3  - doi: 10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
UR  - http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
ER  -